

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Non-small cell lung cancer (NSCLC)	MicroRNA-34a (miR-34a)	<i>In vitro</i> and mouse studies suggest that lipid-mediated delivery of miR-34a could help treat NSCLC. In cultured NSCLC cell lines, miR-34a transfection reduced cell growth compared with scrambled miRNA transfection. In mice, intratumoral and i.v. lipid-mediated delivery of miR-34a reduced growth of subcutaneous NSCLC xenografts without toxicity compared with delivery of scrambled miR-34a. Next steps include further optimization of the pharmacokinetic properties of lipid-formulated miR-34a.	Mirna Therapeutics Inc. has IP covering use of miR-34a in cancer; licensing status undisclosed	Wiggins, J.F. <i>et al. Cancer Res.</i> ; published online June 22, 2010; doi:10.1158/0008-5472.CAN-10-0655 <b>Contact:</b> Andreas G. Bader, Mirna Therapeutics Inc., Austin, Texas e-mail: <a href="mailto:abader@mirnarx.com">abader@mirnarx.com</a>
<p><b>SciBX 3(27); doi:10.1038/scibx.2010.823</b>  <b>Published online July 15, 2010</b></p>				